hydroxychloroquine
hospitalization
Data
Meta-analysis
OR
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.7500
Szente, 2020 0.4500
COPE – Coalition V, 2022 0.7700
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 0.8358
PATCH Cohort 1 (Amaravadi), 2021 2.7931
95%-CI
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 [0.3189; 1.7639]
Szente, 2020 [0.2516; 0.8050]
COPE – Coalition V, 2022 [0.5247; 1.1300]
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 [0.3266; 2.1390]
PATCH Cohort 1 (Amaravadi), 2021 [0.1045; 74.6253]
%W(fixed) %W(random)
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 11.1 11.1
Szente, 2020 24.0 24.0
COPE – Coalition V, 2022 55.0 55.0
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 9.2 9.2
PATCH Cohort 1 (Amaravadi), 2021 0.8 0.8
Number of studies combined: k = 5
OR 95%-CI z p-value
Fixed effect model 0.6868 [0.5167; 0.9129] -2.59 0.0097
Random effects model 0.6868 [0.5167; 0.9129] -2.59 0.0097
Quantifying heterogeneity:
tau^2 = 0 [0.0000; 1.3947]; tau = 0 [0.0000; 1.1810];
I^2 = 0.0% [0.0%; 74.6%]; H = 1.00 [1.00; 1.99]
Test of heterogeneity:
Q d.f. p-value
3.28 4 0.5120
Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2
- Jackson method for confidence interval of tau^2 and tauForest plot - standard presentation
Forest plot - advanced presentation
Sensitivity analysis
method TE ll ul
1 DerSimonian & Laird 0.6867811 0.5166647 0.9129098
2 DerSimonian & Laird, Hartung and Knapp 0.6867811 0.4766983 0.9894481
3 PM 0.6867811 0.5166647 0.9129098
4 PM, Hartung and Knapp 0.6867811 0.4766983 0.9894481
5 REML 0.6840940 0.5049437 0.9268053
6 ML 0.6867811 0.5166647 0.9129098
7 HS 0.6867811 0.5166647 0.9129098
8 SJ 0.6855313 0.4381733 1.0725281
9 HE 0.6867811 0.5166647 0.9129098
10 EB 0.6867811 0.5166647 0.9129098
pval k
1 0.009669684 5
2 0.046063789 5
3 0.009669684 5
4 0.046063789 5
5 0.014261907 5
6 0.009669684 5
7 0.009669684 5
8 0.098259518 5
9 0.009669684 5
10 0.009669684 5
publication bias
OR
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.7500
Szente, 2020 0.4500
COPE – Coalition V, 2022 0.7700
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 0.8358
PATCH Cohort 1 (Amaravadi), 2021 2.7931
Filled: BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 0.5297
Filled: PATCH Cohort 1 (Amaravadi), 2021 0.1585
95%-CI
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 [0.3189; 1.7639]
Szente, 2020 [0.2516; 0.8050]
COPE – Coalition V, 2022 [0.5247; 1.1300]
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 [0.3266; 2.1390]
PATCH Cohort 1 (Amaravadi), 2021 [0.1045; 74.6253]
Filled: BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 [0.2070; 1.3555]
Filled: PATCH Cohort 1 (Amaravadi), 2021 [0.0059; 4.2347]
%W(random)
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 10.1
Szente, 2020 21.8
COPE – Coalition V, 2022 50.1
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 8.3
PATCH Cohort 1 (Amaravadi), 2021 0.7
Filled: BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020 8.3
Filled: PATCH Cohort 1 (Amaravadi), 2021 0.7
Number of studies combined: k = 7 (with 2 added studies)
OR 95%-CI z p-value
Random effects model 0.6654 [0.5072; 0.8729] -2.94 0.0033
Quantifying heterogeneity:
tau^2 = 0 [0.0000; 0.9070]; tau = 0 [0.0000; 0.9523];
I^2 = 0.0% [0.0%; 59.1%]; H = 1.00 [1.00; 1.56]
Test of heterogeneity:
Q d.f. p-value
4.29 6 0.6379
Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2
- Jackson method for confidence interval of tau^2 and tau
- Trim-and-fill method to adjust for funnel plot asymmetry
E-value
script: metaEvidence1.rmd (rfile)